Pertussis cost-effectiveness of therapy: Difference between revisions
Created page with "__NOTOC__ {{Pertussis}} {{CMG}} ; {{AE}} {{ADI}} ==Overview== ==Cost Effectiveness of Therapy== The morbidity and societal cost of pertussis in adults is substantial. A retro..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} ; {{AE}} {{ADI}} | |||
{{Pertussis}} | {{Pertussis}} | ||
==Overview== | ==Overview== | ||
Revision as of 19:47, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
|
Pertussis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pertussis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Pertussis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pertussis cost-effectiveness of therapy |
Overview
Cost Effectiveness of Therapy
The morbidity and societal cost of pertussis in adults is substantial. A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773. If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.[1]
Cost Effectiveness of Vaccination
Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved.